Evaluation of Efficacy and Safety of E004 in Children With Asthma
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blinded, placebo-controlled, parallel, 4-week
study in 60 pediatric patients (4-11 years old) with asthma, comparing E004 with Placebo
HFA-MDI in pediatric patients who are 4-11 years of age with asthma.